Dr Peter Bytzer and colleagues from Denmark evaluated the validity of the Heartburn Reflux Dyspepsia Questionnaire (HRDQ), a newly developed measure of gastro-esophageal reflux disease (GERD) symptoms.
Specifically, the HRDQ was developed for patients, who still experience symptoms with proton pump inhibitor (PPI) treatment.
The psychometric properties of HRDQ were evaluated based on data from 2 clinical trials of patients with GERD with a partial response to PPIs, one from the UK and one from Denmark and Germany.
|An HRDQ cut-off value of 0.70 was the definition of ‘bad day’|
|Scandanavian Journal of Gastroenterology|
The team found that the HRDQ had good internal consistency, and test–retest reliability.
Convergent and discriminant validity were supported by high correlations with ReQuest™, and ability to differentiate between groups based on ReQuest™ cut-off values.
The researchers noted that responsiveness of HRDQ was demonstrated by moderate to high correlations with ReQuest™ change scores and time with symptoms.
The team also evaluated an HRDQ cut-off value of 0.70 for definition of ‘bad day’.
Dr Bytzer's team comments, "Based on existing evidence, the HRDQ is a valid and reliable measure of GERD symptoms that can be used as a study outcome in clinical trials."